Vascular-Targeted Photodynamic Therapy in Prostate Cancer: A New Standard of Care? December 20, 2016 Padeliporfin vascular-targeted photodynamic therapy may be preferable to active surveillance for patients with low-risk, localized prostate cancer, according to a study published in The Lancet Oncology. Read more.Source: Cancer Therapy Advisor Prostate Cancer News
Padeliporfin vascular-targeted photodynamic therapy may be preferable to active surveillance for patients with low-risk, localized prostate cancer, according to a study published in The Lancet Oncology. Read more.Source: Cancer Therapy Advisor
